Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium Tokyo, Japan (May 31, 2013) – Daiichi Sankyo Company, Limited today announced the launch in Japan of Denotas® chewable combination tablets with calcium, natural vitamin D3, magnesium (precipitated calcium carbonate/cholecalciferol (vitamin D3)/magnesium carbonate combination tablets). Nitto Pharmaceutical Industries, Ltd. received approval on February 28, 2013 for the manufacturing and marketing of Denotas® for the treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab). Product overview Launch date: May 31, 2013 Product name DENOTASⓇ CHEWABLE COMBINATION TABLETS Agent Calcium, natural vitamin D3, magnesium combination tablets Drug price 20.90 yen per tablet Announced May 31, 2013 Indications and usage Treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab) Dosage and administration Two tablets to be administered orally every day under normal circumstances. Dosage to be increased or decreased based on condition of the patient and clinical test results. Approval date for manufacturing and marketing February 28, 2013 Manufacturing and marketing Nitto Pharmaceutical Industries, Ltd. Marketing Daiichi Sankyo Co., Ltd.

The release as fetched from its publisher. daiichisankyo.com ↗